Q-omics provides the consensus-scored BRSK1 profile across patient tissues and cancer cell-line models. BRSK1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, BRSK1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, BRSK1 RNA expression shows 19,296 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where BRSK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRSK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRSK1 survival associations across molecular data types. BRSK1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRSK1 RNA expression–survival associations across cancer types. High BRSK1 expression shows unfavorable associations in MESO, KIRC, UVM, ACC, LIHC and LUSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for BRSK1 RNA expression.
This table summarizes BRSK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BRSK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRSK1 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRP, LIHC, LUAD and UCEC. The HNSC box plot shows higher BRSK1 RNA expression in tumor versus normal tissue (log2 FC = +0.682, t-test p < 0.001).
This table shows molecular features associated with BRSK1 in patient tissues and cancer cell lines. In patient samples, BRSK1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BRSK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
